RESUMEN
Pathologic findings showed that neutrophils played an important role in the pathogenesis of NMO. This study aims to investigate the CSF levels of neutrophil-related chemokines in NMO. CXCL1, CXCL5, and CXCL7 were measured in 95 patients with NMO, 15 patients with MS, 18 patients with GFAP astrocytopathy, and 16 controls. The CSF level of CXCL1, CXCL5, and CXCL7 was significantly elevated in the NMO group but not correlated with the patient clinical severity. Besides, the CSF CXCL1, CXCL5, and CXCL7 could act as biomarkers to distinguish NMO from MS with good reliability, especially the CXCL7.
Asunto(s)
Quimiocina CXCL1/líquido cefalorraquídeo , Quimiocina CXCL5/líquido cefalorraquídeo , Neuromielitis Óptica/líquido cefalorraquídeo , Activación Neutrófila , beta-Tromboglobulina/líquido cefalorraquídeo , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neuromielitis Óptica/fisiopatología , Índice de Severidad de la EnfermedadRESUMEN
BACKGROUND: Monocytes are recruited into the cerebrospinal fluid (CSF) of patients with neurosyphilis, suggesting abnormal chemokine expression. We aimed to investigate the aberrant expression of chemokines in the CSF of these patients. METHODS: CSF and serum samples were collected from patients with neurosyphilis between July 2017 and June 2019 in the Dermatology Department, Second Affiliated Hospital of Zhejiang University. Differences in the expression of 38 chemokines between patients with and without neurosyphilis were detected using RayBio® Human Chemokine Antibody Array C1. CCL24 and CXCL7 levels in the patients' CSF and serum were further measured using RayBio® CCL24 and CXCL7 ELISA kits. RESULTS: Ninety-three CSF and serum samples of patients with syphilis were collected. Antibody array analysis showed that the CSF levels of CCL24 (P = .0185), CXCL7 (P < .0001), CXCL13 (P < .0001), CXCL10 (P < .0001), and CXCL8 (P < .0001) were significantly higher in patients with than without neurosyphilis. ELISA confirmed significantly higher CCL24 and CXCL7 levels in the CSF of patients with than without neurosyphilis (CCL24: 6.082 ± 1.137 pg/mL vs 1.773 ± 0.4565 pg/mL, P = .0037; CXCL7: 664.3 ± 73.19 pg/mL vs 431.1 ± 90.54 pg/mL, P = .0118). Increased CCL24 and CXCL7 expression was seen throughout all neurosyphilis stages, had moderate diagnostic efficiency for neurosyphilis, and correlated poorly with CSF cell count and Venereal Disease Research Laboratory titer. CSF CCL24 levels also correlated poorly with CSF protein concentration. CONCLUSION: Abnormally high CSF chemokines levels may play a role in the pathogenesis of neurosyphilis.
Asunto(s)
Biomarcadores/líquido cefalorraquídeo , Quimiocina CCL24/líquido cefalorraquídeo , Neurosífilis/diagnóstico , beta-Tromboglobulina/líquido cefalorraquídeo , Biomarcadores/sangre , Quimiocina CCL24/sangre , Estudios de Seguimiento , Humanos , Neurosífilis/sangre , Neurosífilis/líquido cefalorraquídeo , Pronóstico , Estudios Retrospectivos , beta-Tromboglobulina/análisisRESUMEN
Accumulating evidence from epidemiological, clinical and experimental studies suggests that vascular risk factors and angiopathic mechanisms are involved in the pathogenesis of Alzheimer's disease (AD). Platelets could be the missing link between AD and the vasculature. Soluble glycoprotein VI (sGPVI) and beta-thromboglobulin (beta-TG) plasma and cerebrospinal fluid (CSF) levels as markers of platelet activity were measured in 30 AD patients and 20 age-matched healthy elderly controls by ELISA. The severity of dementia was assessed by mini-mental state examination (MMSE). We found in AD patients significantly decreased sGPVI plasma levels (0.55+/-0.18ng/ml) as compared to healthy controls (0.75+/-0.43ng/ml; p=0.033). In AD patients, sGPVI levels were positively correlated with beta-TG plasma levels (r=0.244, p=0.05) and with cognitive status as measured by MMSE score (r=0.271; p=0.048). In unconcentrated CSF samples, levels of beta-TG and sGPVI were below the detection limit of the assays in AD patients and healthy controls. Our results suggest an association of sGPVI with the pathogenesis of AD. These findings encourage future research into whether sGPVI plasma levels may reflect or even mediate neuroprotective mechanisms in AD.
Asunto(s)
Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/líquido cefalorraquídeo , Glicoproteínas de Membrana Plaquetaria/metabolismo , beta-Tromboglobulina/metabolismo , Anciano , Enfermedad de Alzheimer/diagnóstico , Trastornos del Conocimiento/diagnóstico , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Proyectos Piloto , Plasma , Glicoproteínas de Membrana Plaquetaria/líquido cefalorraquídeo , Índice de Severidad de la Enfermedad , beta-Tromboglobulina/líquido cefalorraquídeoRESUMEN
The aim of this study was to determine the concentration of PDGF in vivo in neoplastic and non-neoplastic brain lesions. Fluid from cystic lesions and cerebrospinal fluid was tested in a radioreceptor assay that detects all described PDGF isoforms. High concentration of PDGF were found in cyst fluids from several astrocytomas, one metastatic melanoma, one metastatic lung adenocarcinoma and one intracerebral abscess. The PDGF concentrations were several times higher than the levels known to be required for maximal PDGF effects on cells in vitro. PDGF could also be detected in some non-neoplastic lesions, especially one intracerebral abscess. The finding of high amounts of PDGF in neoplastic lesions strongly supports the possibility that PDGF can be a mediator of tumour and stromal cell growth and motility in vivo. Comparison of PDGF and beta-thromboglobulin concentrations in the same fluids strongly indicates that the PDGF protein is locally produced rather than a result of platelet activation and derangement of the blood-brain barrier.
Asunto(s)
Astrocitoma/química , Neoplasias Encefálicas/química , Quistes/química , Factor de Crecimiento Derivado de Plaquetas/análisis , beta-Tromboglobulina/análisis , Astrocitoma/líquido cefalorraquídeo , Neoplasias Encefálicas/líquido cefalorraquídeo , Quistes/líquido cefalorraquídeo , Humanos , Factor de Crecimiento Derivado de Plaquetas/líquido cefalorraquídeo , beta-Tromboglobulina/líquido cefalorraquídeoRESUMEN
Fibrinopeptide A (FPA), platelet-secreted protein, platelet factor 4 and beta-thromboglobulin were determined in the cerebrospinal fluid of patients who had suffered from subarachnoid hemorrhage and were treated with 6 g tranexamic acid or 4 million KIU aprotinin to prevent rebleeding. Platelet-secreted proteins and FPA were cleared from the cerebrospinal fluid within 3 days after bleeding. Their vasoactive and thrombotic capability is limited to the initiation period of vasospasm that usually comes to clinical observation 3-8 days after bleeding. Increased thrombotic activity of the cerebrospinal fluid, as reflected by high levels of FPA and platelet-secreted protein, seemed to promote the occurrence of neurological deficits.